-49%

est. 2Y upside i

HealthcareSeries A

Rank

#457

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Vivodyne presents a strong upside opportunity driven by its innovative AI-powered human tissue testing platform, addressing a critical need in drug development and benefiting from favorable regulatory shifts.

Last updated: March 10, 2026

Bull (30%)+350%

Vivodyne's platform becomes the industry standard for preclinical testing, driven by strong regulatory mandates and proven superior predictive accuracy. Key partnerships expand rapidly, pushing revenue to over $100M by 2028 and justifying a $1.2B+ valuation at a premium multiple, leading to a successful acquisition or IPO.

Base (45%)+75%

Vivodyne continues steady growth, securing additional partnerships and expanding its platform capabilities. It maintains a strong niche in the preclinical testing market, growing revenue to ~$30M by 2028 and achieving a ~$480M valuation, offering a moderate return for early equity holders.

Bear (25%)-80%

Incumbent pharmaceutical companies develop similar in-house capabilities or partner with other emerging biotech firms, limiting Vivodyne's market penetration. High capital intensity leads to slower growth than expected, resulting in a down round to a $55M valuation, significantly eroding common stock value given the preference stack.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $79.6M in liquidation preferences. In an exit at or below the estimated $275M valuation, common shareholders would see reduced returns, potentially nothing if the exit is below $79.6M.

Dilution Risk

high

As a Series A company with $7M revenue, Vivodyne will almost certainly require additional funding rounds (e.g., Series B, C) to reach profitability or an exit, leading to further dilution of existing equity.

Secondary Liquidity

limited

While Vivodyne stock is not publicly traded, platforms like Nasdaq Private Market allow accredited investors to buy/sell shares, indicating some limited secondary liquidity for employee equity.

Other — 4 roles

View all 4 open roles at Vivodyne →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Vivodyne's data — designed to show you've done your homework.

  • 1

    “Given the strong regulatory tailwind and the shift away from animal testing, how is Vivodyne strategically positioning itself to capture a dominant share of the preclinical testing market, particularly against established CROs like Charles River Laboratories and potential in-house development by large pharmaceutical companies?”

  • 2

    “With $7M in revenue and a high capital intensity business, what are the key milestones and financial targets Vivodyne aims to achieve in the next 24 months to demonstrate a clear path to profitability or a significantly higher valuation for future funding rounds?”

  • 3

    “Considering the $79.6M in total funding and the Series A stage, how is the company thinking about managing future dilution for employees, and what is the anticipated timeline and strategy for a liquidity event for common shareholders?”

Community

Valuation Sentiment

Our model estimates -49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.